Morphic Holding Inc (MORF)

$23.455

+0.2

(+0.88%)▲

Market is closed - opens 8 PM, 29 Nov 2023

Insights on Morphic Holding Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 521.0K → 60.23M (in $), with an average increase of 99.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -39.01M → -36.21M (in $), with an average increase of 7.7% per quarter

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 76.9% return, outperforming this stock by 89.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 26.8% return, outperforming this stock by 54.3%

Performance

  • $22.60
    $23.46
    $23.46
    downward going graph

    3.67%

    Downside

    Day's Volatility :3.67%

    Upside

    0.0%

    downward going graph
  • $19.35
    $63.08
    $23.46
    downward going graph

    17.52%

    Downside

    52 Weeks Volatility :69.32%

    Upside

    62.81%

    downward going graph

Returns

PeriodMorphic Holding IncSector (Health Care)Index (Russel 2000)
3 Months
-57.56%
-2.6%
0.0%
6 Months
-59.49%
2.2%
0.0%
1 Year
-12.63%
-4.3%
-3.4%
3 Years
-25.88%
19.1%
-4.7%

Highlights

Market Capitalization
1.2B
Book Value
$14.54
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.29
Wall Street Target Price
59.38
Profit Margin
0.0%
Operating Margin TTM
-2341.29%
Return On Assets TTM
-17.2%
Return On Equity TTM
-24.95%
Revenue TTM
6.7M
Revenue Per Share TTM
0.16
Quarterly Revenue Growth YOY
-78.10000000000001%
Gross Profit TTM
-31.3M
EBITDA
-154.8M
Diluted Eps TTM
-3.29
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.4
EPS Estimate Next Year
-3.88
EPS Estimate Current Quarter
-0.95
EPS Estimate Next Quarter
-1.02

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Morphic Holding Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
15
Hold
3
3
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 153.17%

Current $23.46
Target $59.38

Technicals Summary

Sell

Neutral

Buy

Morphic Holding Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Morphic Holding Inc
Morphic Holding Inc
13.97%
-59.49%
-12.63%
-25.88%
29.17%
Moderna, Inc.
Moderna, Inc.
4.93%
-38.23%
-55.68%
-49.12%
317.85%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.62%
9.54%
7.63%
54.66%
119.47%
Novo Nordisk A/s
Novo Nordisk A/s
7.75%
29.99%
71.36%
209.46%
351.9%
Seagen, Inc.
Seagen, Inc.
0.13%
10.52%
76.89%
25.9%
249.5%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.03%
7.65%
11.07%
53.76%
96.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Morphic Holding Inc
Morphic Holding Inc
NA
NA
NA
-3.4
-0.25
-0.17
0.0
14.54
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.11
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.51
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.76
41.76
2.03
2.65
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.68
26.68
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Morphic Holding Inc
Morphic Holding Inc
Buy
$1.2B
29.17%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$29.8B
317.85%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
119.47%
22.78
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$458.4B
351.9%
41.76
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
249.5%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.4B
96.32%
26.68
35.94%

Institutional Holdings

  • FMR Inc

    14.34%

  • EcoR1 Capital, LLC

    8.03%

  • BlackRock Inc

    5.74%

  • Wellington Management Company LLP

    4.81%

  • T. Rowe Price Associates, Inc.

    4.57%

  • Artal Group S A

    4.47%

Corporate Announcements

  • Morphic Holding Inc Earnings

    Morphic Holding Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

Organization
Morphic Holding Inc
Employees
115
CEO
Dr. Praveen P. Tipirneni M.D.
Industry
Health Technology

Discover More

FAQs